

Docetaxel Q3w TAX 327 study

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Docetaxel Q3w TAX 327 study

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer
Experimental Arm: Docetaxel Q3w + Prednisone or prednisolone
Control Arm: Mitoxantrone ± prednisone or prednisolone

